Metastatic rhabdoid meningioma with BRAF V600E mutation and good response to personalized therapy: Case report and review of the literature

Oz Mordechai; Sergey Postovsky; Eugene Vlodavsky; Ayelet Eran; Shlomi Constantini; Eynat Dotan; Emmanuela Cagnano; Myriam Weyl-Ben-Arush

doi:10.3109/08880018.2014.936058

Metastatic rhabdoid meningioma with BRAF V600E mutation and good response to personalized therapy: Case report and review of the literature

Oz Mordechai
, Sergey Postovsky
, Eugene Vlodavsky
, Ayelet Eran
, Shlomi Constantini
, Eynat Dotan
, Emmanuela Cagnano
, Myriam Weyl-Ben-Arush^*

^*Corresponding author for this work

Rambam Health Care Campus Israel
Technion-Israel Institute of Technology
Rambam Health Care Campus
Tel Aviv Sourasky Medical Center

Research output: Contribution to journal › Article › peer-review

27 Scopus citations

Abstract

Rhabdoid meningioma is an aggressive phenotype of meningioma, associated with a poor prognosis. We present a very rare case of high-grade meningioma with rhabdoid features that eventually expressed in a coma state. Comprehensive genomic profiling using a Next Generation Sequencing (NGS) assay revealed three genomic alterations: activating BRAF mutation (V600E), loss of CDKN2A/2B, and APC I1307K. After treatment with BRAF inhibitor (dabrafenib), the child's clinical condition improved progressively. After seven months, an MEK inhibitor was added (trametinib).

Original language	English
Pages (from-to)	207-211
Number of pages	5
Journal	Pediatric Hematology and Oncology
Volume	32
Issue number	3
DOIs	https://doi.org/10.3109/08880018.2014.936058
State	Published - 3 Apr 2015
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

BRAF mutation
MEK inhibitor
Meningioma
Targeted therapy

Access to Document

10.3109/08880018.2014.936058

Cite this

@article{6b59adeb2fbc4c2097640870017fc825,

title = "Metastatic rhabdoid meningioma with BRAF V600E mutation and good response to personalized therapy: Case report and review of the literature",

abstract = "Rhabdoid meningioma is an aggressive phenotype of meningioma, associated with a poor prognosis. We present a very rare case of high-grade meningioma with rhabdoid features that eventually expressed in a coma state. Comprehensive genomic profiling using a Next Generation Sequencing (NGS) assay revealed three genomic alterations: activating BRAF mutation (V600E), loss of CDKN2A/2B, and APC I1307K. After treatment with BRAF inhibitor (dabrafenib), the child's clinical condition improved progressively. After seven months, an MEK inhibitor was added (trametinib).",

keywords = "BRAF mutation, MEK inhibitor, Meningioma, Targeted therapy",

author = "Oz Mordechai and Sergey Postovsky and Eugene Vlodavsky and Ayelet Eran and Shlomi Constantini and Eynat Dotan and Emmanuela Cagnano and Myriam Weyl-Ben-Arush",

note = "Publisher Copyright: {\textcopyright} 2015 Informa Healthcare USA, Inc.",

year = "2015",

month = apr,

day = "3",

doi = "10.3109/08880018.2014.936058",

language = "אנגלית",

volume = "32",

pages = "207--211",

journal = "Pediatric Hematology and Oncology",

issn = "0888-0018",

number = "3",

}

TY - JOUR

T1 - Metastatic rhabdoid meningioma with BRAF V600E mutation and good response to personalized therapy

T2 - Case report and review of the literature

AU - Mordechai, Oz

AU - Postovsky, Sergey

AU - Vlodavsky, Eugene

AU - Eran, Ayelet

AU - Constantini, Shlomi

AU - Dotan, Eynat

AU - Cagnano, Emmanuela

AU - Weyl-Ben-Arush, Myriam

PY - 2015/4/3

Y1 - 2015/4/3

N2 - Rhabdoid meningioma is an aggressive phenotype of meningioma, associated with a poor prognosis. We present a very rare case of high-grade meningioma with rhabdoid features that eventually expressed in a coma state. Comprehensive genomic profiling using a Next Generation Sequencing (NGS) assay revealed three genomic alterations: activating BRAF mutation (V600E), loss of CDKN2A/2B, and APC I1307K. After treatment with BRAF inhibitor (dabrafenib), the child's clinical condition improved progressively. After seven months, an MEK inhibitor was added (trametinib).

AB - Rhabdoid meningioma is an aggressive phenotype of meningioma, associated with a poor prognosis. We present a very rare case of high-grade meningioma with rhabdoid features that eventually expressed in a coma state. Comprehensive genomic profiling using a Next Generation Sequencing (NGS) assay revealed three genomic alterations: activating BRAF mutation (V600E), loss of CDKN2A/2B, and APC I1307K. After treatment with BRAF inhibitor (dabrafenib), the child's clinical condition improved progressively. After seven months, an MEK inhibitor was added (trametinib).

KW - BRAF mutation

KW - MEK inhibitor

KW - Meningioma

KW - Targeted therapy

UR - https://www.scopus.com/pages/publications/84928159574

U2 - 10.3109/08880018.2014.936058

DO - 10.3109/08880018.2014.936058

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 25116269

AN - SCOPUS:84928159574

SN - 0888-0018

VL - 32

SP - 207

EP - 211

JO - Pediatric Hematology and Oncology

JF - Pediatric Hematology and Oncology

IS - 3

ER -

Metastatic rhabdoid meningioma with BRAF V600E mutation and good response to personalized therapy: Case report and review of the literature

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this